A Healthy Future in Pharma Starts with Sustainable Packaging

A Healthy Future in Pharma Starts with Sustainable Packaging

The pharmaceutical industry plays a vital role in global healthcare, and packaging is a big part of how that role is delivered. A blister, a vial, a carton and a leaflet are not incidental. They protect the molecule, carry the instructions, and keep the medicine safe from the factory floor to the patient's hand.

Introduction

The pharmaceutical industry plays a vital role in global healthcare, and packaging is a big part of how that role is delivered. A blister, a vial, a carton and a leaflet are not incidental. They protect the molecule, carry the instructions, and keep the medicine safe from the factory floor to the patient's hand.

That same packaging also carries an environmental cost. Plastics, aluminium, glass and paper all draw on finite resources, and much of what protects a medicine is used once and discarded. The encouraging part is that this is changing, and faster than it has in years. Materials science has moved on. Regulation has moved on too. The EU Packaging and Packaging Waste Regulation, Regulation (EU) 2025/40, was adopted in December 2024 and applies from 12 August 2026, and comparable extended producer responsibility rules are now live in India and across several US states.

For manufacturers, the question is no longer whether sustainable packaging matters. It is which changes hold up under stability testing, regulatory scrutiny and real supply chain conditions, and which are simply good intentions in a nicer wrapper.

The Environmental Impact of Pharmaceutical Packaging

For decades the industry has relied on plastics, aluminium and glass. These materials do their job well. They resist moisture, block light, survive shipping and keep products stable for years. Their environmental profile is where the difficulty lies.

Some context helps. The world generates roughly 350 million tonnes of plastic waste every year across all industries, according to the OECD's Global Plastic Outlook. Pharmaceutical packaging is a small share of that total, but a stubborn one. Around 100,000 tonnes of plastic are produced each year specifically for medicine packaging, and roughly 85% of solid unit doses in Europe are supplied in blisters. Healthcare as a whole accounts for about 4.4% of global net emissions, equivalent to two gigatonnes of CO2e, in the widely cited Health Care Without Harm and Arup analysis.

Blisters are the hardest case. A typical blister bonds aluminium foil to a plastic base with adhesive layers, which makes the materials very difficult to separate at end of life. PVC and PVDC are not accepted in most standard recycling streams and can contaminate other plastics if they enter them. Residual product in a used blister raises a further question about active ingredients reaching the environment. These are engineering problems, not attitude problems, and they are the reason progress has taken time.

Sustainable Packaging Solutions

Several routes are now genuinely commercial rather than experimental.

  • Mono-material and PVC-free structures. Replacing a multi-layer laminate with a single polymer family makes a pack recyclable in principle. Bayer and Liveo Research launched a PVC-free mono-PET blister for Aleve in the Netherlands in October 2024, with a third-party-verified life cycle assessment showing a 38% lower carbon footprint per unit, 78% less water use and an 18% lighter pack. Suppliers including Amcor, with its polyethylene-based AmSky structure, and Sudpack Medica, with the mono-polypropylene PharmaGuard film, report reductions of up to 70% and 47% respectively against conventional PVC and aluminium constructions. Those two are supplier-stated figures rather than independently verified, and are worth treating as such.
  • Bio-based plastics. Astellas used sugarcane-derived polyethylene for the blister packaging of Irribow tablets in Japan in 2021, with biomass accounting for around half the raw material in the pack. Materials such as NatureWorks' Ingeo PLA continue to mature, though their application so far sits mainly in food and consumer packaging rather than pharmaceutical primary packs.
  • Extended producer responsibility. EPR shifts accountability for a pack across its whole life onto the company that places it on the market. Under the EU's PPWR, design-for-recycling criteria, recycled content requirements and reuse obligations phase in through 2030 and beyond. Immediate packaging of medicinal products carries specific derogations, because patient safety takes precedence, but EPR fees still apply. India brought amended Plastic Waste Management requirements into effect from 1 July 2025, with on-pack barcodes, QR codes or unique identifiers, CPCB registration numbers and annual returns through the central EPR portal. Seven US states now have packaging EPR laws in force or phasing in, with registration and reporting deadlines running through 2027.
  • Recycled materials. This is where honesty matters. Recycled content is largely restricted in primary pharmaceutical packaging by design, for contamination and traceability reasons, and both EU and Indian rules acknowledge that. The real opportunity sits in secondary and tertiary packaging: cartons, inserts, shippers and pallets, where recycled fibre and recycled plastic are already viable. GSK has committed to a 25% reduction in the environmental impact of its products and packaging by 2030, and Pfizer states that it selects packaging that maximises recycled materials where regulation allows.
  • Paper-based packaging. Huhtamaki's Push Tab paper blister, developed with Syntegon, uses more than 75% certified paper and is aimed squarely at pharmaceuticals and nutraceuticals. Smurfit Westrock's PharmaLock paperboard provides paper backing for blister cards. These reduce plastic meaningfully, though most still pair paper with a barrier layer, so they are a substantial improvement rather than a clean substitution.
  • QR codes and electronic labelling. Moving the patient leaflet from paper to a scan removes printed material from every pack. Prescription medicines in the EU have carried a 2D Data Matrix unique identifier since February 2019 under the Falsified Medicines Directive. Electronic product information is progressing separately, with the EMA publishing a draft delivery roadmap in March 2026, positioned for now as an addition to existing formats rather than a replacement. Japan has gone furthest, having abolished paper package inserts in principle for prescription medicines from August 2021, with access provided through barcode scanning.
  • Advanced materials. Aerogels and nanomaterials appear regularly in discussions of next-generation packaging. Published work to date sits mainly in active food packaging and drug delivery rather than pharmaceutical packs, so this is best treated as a research direction to watch rather than an available option.

Benefits of Sustainable Packaging

A smaller environmental footprint. The direct gain is the obvious one: less virgin material, less landfill, fewer emissions across the pack's life. Cost that improves rather than worsens.

The most reliable saving is not a different material but less material. A peer-reviewed life cycle assessment of pharmaceutical packaging found that impacts varied by up to five times between packaging options for the same medicine, and that compact formats which avoid empty space reduce environmental impact and production cost together. Right-sizing a carton is available to almost every manufacturer today, needs no new supplier and rarely requires a regulatory variation.

Commercial readiness. Customers increasingly need packaging data from their suppliers, by material type and weight, to file their own EPR returns and to complete Scope 3 reporting. A manufacturer who can supply that data cleanly removes work from the customer's side. A manufacturer who cannot becomes the gap in someone else's compliance file.

Challenges in Adopting Sustainable Packaging

  • Regulatory compliance. A packaging change is a regulated change. New materials require a fresh stability programme under ICH Q1, including long-term, accelerated and photostability studies, plus an extractables and leachables assessment, followed by variation filings in every market where the product is registered. The IFPMA has noted that post-approval changes can take three to five years to be approved across markets, which is why packaging decisions are made years before consumers see them.
  • Technical trade-offs. Barrier performance is the constraint. Moisture and oxygen ingress determine shelf life, and a pack that fails on barrier converts saved packaging carbon into lost product. A medicine that expires early is a far larger environmental cost than the film that was meant to be greener.
  • Assumptions that do not survive testing. The intuitive villain is not always the culprit. One peer-reviewed assessment found PVC forming film had the lowest environmental impacts of the films studied, with aluminium-containing structures scoring worse on acidification. Recyclable is also not the same as recycled: a pack can be technically recyclable and still have nowhere to go if collection infrastructure does not exist for it.
  • Supply chain complexity. Sustainability gains have to survive procurement, manufacturing, distribution and disposal. A material improvement that adds three transport legs is not an improvement.

Progress on all four fronts depends on collaboration. When manufacturers, packaging suppliers and regulators work through material qualification together, the timeline compresses and the evidence base strengthens for everyone. Research investment matters too, and the industry has shown what is possible when it focuses: a Cornell study published in 2023 found that the carbon footprint of producing a single drug, tenofovir disoproxil fumarate, could be cut by around 45% through process and sourcing changes.

Where This Leaves Manufacturers

The practical path forward is unglamorous and effective. Start with what does not require a variation, which is usually secondary packaging, carton right-sizing and shipper optimisation. Build the packaging data set your customers need for their EPR and Scope 3 reporting, because they will ask. Qualify mono-material and PVC-free options now, so that the stability data exists when a customer or a regulation asks for the switch. 

The practical path forward is unglamorous and effective. Four moves matter more than the rest, in this order.

  1. Start with what doesn't require a variation. Usually secondary packaging — carton right-sizing and shipper optimisation. Available now, no filings needed, and it removes weight and cost together.
  2. Qualify mono-material and PVC-free options now. So the stability data exists before a customer or regulation asks for the switch. Qualification is slow; being asked and having to start is slower.
  3. Build the packaging data set your customers need. By material type and weight, ready for EPR filings and Scope 3 reporting. They will ask — the manufacturer who can supply it cleanly wins the shortlist.
  4. Test every claim against a life cycle assessment. Not intuition. The intuitive villain isn't always the carbon-heaviest choice — the numbers should decide, backed by verified methodology.

Sustainable packaging is not a marketing exercise in this industry. It is a materials, stability and compliance exercise that happens to have an environmental benefit at the end of it.

Key Takeaways

  • The question is no longer whether sustainable pharmaceutical packaging matters, but which changes hold up under stability testing, regulatory scrutiny and real supply chain conditions — and which are simply good intentions in a nicer wrapper.
  • Blisters are the hardest case. Multi-layer PVC / PVDC laminates are not accepted in most standard recycling streams and can contaminate other plastics — which is why mono-material and PVC-free structures are the most consequential shift in the last 24 months.
  • The most reliable saving is not a different material — it is less material. Right-sizing cartons, optimising shippers and eliminating empty space reduce cost and carbon together, and rarely require a regulatory variation.
  • Recycled content is largely restricted in primary pharmaceutical packaging by design. The real opportunity sits in secondary and tertiary packaging, and in the EPR-ready data manufacturers can now supply to customers filing their own Scope 3 reports.
  • Progress depends on collaboration between manufacturers, packaging suppliers and regulators — and on testing every claim against a life cycle assessment rather than intuition, because the intuitive villain isn't always the carbon-heaviest choice.

References

  • OECD. (2022). Global Plastic Outlook: Economic Drivers, Environmental Impacts and Policy Options. OECD Publishing. oecd.org/environment/plastics
  • Health Care Without Harm & Arup. (2019). Health care's climate footprint: how the health sector contributes to the global climate crisis and opportunities for action. noharm-global.org
  • European Parliament & Council. (2024). Regulation (EU) 2025/40 on Packaging and Packaging Waste (PPWR). Adopted December 2024; applies from 12 August 2026.
  • Central Pollution Control Board, Government of India. (2025). Plastic Waste Management (Amendment) Rules. Effective 1 July 2025.
  • European Medicines Agency. (2026). Draft delivery roadmap: Electronic Product Information (ePI) for human medicines. March 2026.
  • International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Guidance on post-approval change management.
  • Bayer & Liveo Research. (2024). PVC-free mono-PET blister life cycle assessment (Aleve, Netherlands launch).
  • Cornell University. (2023). Life cycle assessment of tenofovir disoproxil fumarate production pathway.